5月16日,复星医药(600196/02196)发布公告,控股子公司上海复宏汉霖生物技术股份有限公司及其控股子公司于近日启动了伊匹木单抗生物类似药HLX13在中国境内针对不可切除的晚期肝细胞癌患者的I/III期临床试验。HLX13为公司自主研发的生物类似药,计划用于治疗多种癌症,包括黑色素瘤和肾细胞癌等。截至2025年4月,针对HLX13的研发累计投入约为1.04亿元。根据IQVIA MIDAS™...
Source Link5月16日,复星医药(600196/02196)发布公告,控股子公司上海复宏汉霖生物技术股份有限公司及其控股子公司于近日启动了伊匹木单抗生物类似药HLX13在中国境内针对不可切除的晚期肝细胞癌患者的I/III期临床试验。HLX13为公司自主研发的生物类似药,计划用于治疗多种癌症,包括黑色素瘤和肾细胞癌等。截至2025年4月,针对HLX13的研发累计投入约为1.04亿元。根据IQVIA MIDAS™...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.